The economics of abiraterone acetate for castration-resistant prostate cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 2, 2014, Pages 175-179

  Dellis, Athanasios ^a,b   Papatsoris, Athanasios G ^a,c,d,e  

^a SISMANOGLIO HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Hellenic Group of Genitourinary Cancer   (Greece)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e Institute of Molecular Medicine and Biomedical Research   (Greece)

Author keywords

Abiraterone acetate; Castration resistant; Cost benefit; Economics; Metastatic; Prostate cancer

Indexed keywords

ABIRATERONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE;

ARTICLE; BUDGET; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HEALTH CARE COST; HUMAN; METASTASIS; OVERALL SURVIVAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; ECONOMICS; MALE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY ADJUSTED LIFE YEAR;

ANDROSTADIENES; COST-BENEFIT ANALYSIS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY-ADJUSTED LIFE YEARS;

EID: 84896258400     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.891444     Document Type: Article

References (22)

1. Sorensen S, Ellis L, Wu Y, et al. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm 2013;19(9):799-808
2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467-79
3. Vasani D, Josephson DY, Carmichael C, et al. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas 2011;70(2):194-6
4. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
5. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28(9):1481-8
6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
7. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
8. Arrabal-Martín M, Anglada-Curado F, Cózar-Olmo JM, et al. Pre-chemotherapy abiraterone acetate. a proposal of a treatment algorithm in castration resistant prostate cancer. Actas Urol Esp 2013. [Epub ahead of print]
9. Procopio G, Grassi P, Testa I, et al. Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors. Am J Clin Oncol 2013. [Epub ahead of print]
10. Zeliadt SB, Penson DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics 2007; 25(4):309-27
11. Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis 2002;5(2):164-6
12. Hatoum HT, Crawford ED, Nielsen SK, et al. Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res 2013;13(2): 251-9
13. Hart W, Nazir J, Baskin-Bey E. An incidence model of the cost of advanced prostate cancer in Spain. J Med Econ 2014; 17(2):125-31
14. Ning YM, Pierce W, Maher VE, et al. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: u.s. Food and drug administration drug approval summary. Clin Cancer Res 2013; 19(22):6067-73
15. Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24(7): 1802-7
16. Peer A, Gottfried M, Sinibaldi V, et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2014;74(4):433-40
17. Wilson L, Tang J, Zhong L, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract 2013. [Epub ahead of print]
18. Collins R, Fenwick E, Trowman R, et al. A systematic review and economic model of the clinical effectiveness and costeffectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007;11(2):1-179
19. Zhong L, Pon V, Srinivas S, et al. Therapeutic Options in Docetaxel- Refractory Metastatic Castration-Resistant Prostate Cancer: a Cost- Effectiveness Analysis. PLoS One 2013;22:8(5):e64275
20. Dellis A, Papatsoris AG. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer. Expert Opin Biol Ther 2014;14(1):7-10
21. Carter JA, Joshi AD, Kaura S, Botteman MF. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics 2012;30(5): 373-86
22. Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15(4):712-23